Conferences \ BioProcessing, Biologics & Biotherapeutics Congress \ Antibody and Peptide Therapeutics \ Agenda \ Roy Jefferis |
Register | Login |
Glycosylation of IgG Antibodies: a Critical Quality Attribute (CQA)Wednesday, 20 July 2011 at 16:30 Add to Calendar ▼2011-07-21 10:00:002011-07-21 11:00:00Europe/LondonBiosimilars, Bio-betters, Comparability and Adverse ReactionsSELECTBIOenquiries@selectbiosciences.com The biologic activities of natural IgG antibodies are determined by the glycoform profile; orchestrated by the immune system. Production cell lines deliver a fixed glycoform profile; therefore, resort is made to cell and protein engineering. Biosimilars, Bio-betters, Comparability and Adverse ReactionsThursday, 21 July 2011 at 10:00 Add to Calendar ▼2011-07-21 10:00:002011-07-21 11:00:00Europe/LondonBiosimilars, Bio-betters, Comparability and Adverse ReactionsSELECTBIOenquiries@selectbiosciences.com The first essential for a biosimilar is that the sequence is identical to that of the innovator protein. However, bulk recombinant proteins are structurally heterogeneous and control over post-translational modifications presents a formidable challenge. |